5:38 PM
 | 
Jan 02, 2018
 |  BC Extra  |  Company News

Allergan among companies unveiling price hikes

Allergan plc (NYSE:AGN) raised the price of 18 drugs by 9.5%, just under the company's pledge to limit yearly price increases to single digits, according to a Jefferies report.

Allergan spokesperson Mark Marmur told BioCentury the company increased its average list price of drugs for 2018 by 7.3% and expects a net increase of about 2-3% after discounts and rebates. Last year, Allergan increased the average list price of its drugs by 6.7%.

For the nine months ended Sept. 30, 2017, Allergan posted sales for dry eye drug Restasis cyclosporine and gastrointestinal drug Linzess linaclotide -- the two highest selling products in the Jefferies report -- of $1.1 billion and $522.4 million, respectively. Marmur did not confirm...

Read the full 562 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >